Evasion of the interferon-mediated antiviral response by filoviruses.

Washington B Cárdenas
Author Information
  1. Washington B Cárdenas: Laboratorio de Biomedicina, FIMCM, Escuela Superior Politécnica del Litoral (ESPOL), Campus Gustavo Galindo, Km 30.5 via Perimetral, Apartado 09-01-5863, Guayaquil, Ecuador. ORCID

Abstract

The members of the filoviruses are recognized as some of the most lethal viruses affecting human and non-human primates. The only two genera of the Filoviridae family, Marburg virus (MARV) and Ebola virus (EBOV), comprise the main etiologic agents of severe hemorrhagic fever outbreaks in central Africa, with case fatality rates ranging from 25 to 90%. Fatal outcomes have been associated with a late and dysregulated immune response to infection, very likely due to the virus targeting key host immune cells, such as macrophages and dendritic cells (DCs) that are necessary to mediate effective innate and adaptive immune responses. Despite major progress in the development of vaccine candidates for filovirus infections, a licensed vaccine or therapy for human use is still not available. During the last ten years, important progress has been made in understanding the molecular mechanisms of filovirus pathogenesis. Several lines of evidence implicate the impairment of the host interferon (IFN) antiviral innate immune response by MARV or EBOV as an important determinant of virulence. In vitro and in vivo experimental infections with recombinant Zaire Ebola virus (ZEBOV), the best characterized filovirus, demonstrated that the viral protein VP35 plays a key role in inhibiting the production of IFN-α/β. Further, the action of VP35 is synergized by the inhibition of cellular responses to IFN-α/β by the minor matrix viral protein VP24. The dual action of these viral proteins may contribute to an efficient initial virus replication and dissemination in the host. Noticeably, the analogous function of these viral proteins in MARV has not been reported. Because the IFN response is a major component of the innate immune response to virus infection, this chapter reviews recent findings on the molecular mechanisms of IFN-mediated antiviral evasion by filovirus infection.

Keywords

References

  1. Annu Rev Immunol. 2003;21:107-37 [PMID: 12414720]
  2. J Infect Dis. 2003 Dec 1;188(11):1630-8 [PMID: 14639532]
  3. Cell Microbiol. 2007 Apr;9(4):962-76 [PMID: 17381429]
  4. J Infect Dis. 1999 Feb;179 Suppl 1:S218-23 [PMID: 9988187]
  5. J Virol. 2007 Dec;81(24):13469-77 [PMID: 17928350]
  6. J Immunol. 2003 Mar 15;170(6):2797-801 [PMID: 12626527]
  7. Wkly Epidemiol Rec. 2009 Feb 13;84(7):49-50 [PMID: 19219963]
  8. J Gen Virol. 2001 Jun;82(Pt 6):1365-1373 [PMID: 11369881]
  9. Science. 2003 Aug 1;301(5633):640-3 [PMID: 12855817]
  10. J Virol. 1999 Apr;73(4):3491-6 [PMID: 10074208]
  11. PLoS One. 2007 Aug 22;2(8):e764 [PMID: 17712412]
  12. J Virol. 2006 Jun;80(11):5168-78 [PMID: 16698997]
  13. J Exp Med. 2005 Mar 21;201(6):915-23 [PMID: 15767370]
  14. Wkly Epidemiol Rec. 2005 Oct 28;80(43):370-5 [PMID: 16285261]
  15. Mol Cell. 2005 Sep 16;19(6):727-40 [PMID: 16153868]
  16. J Virol. 2009 Sep;83(17):8993-7 [PMID: 19515768]
  17. J Immunol. 2008 Mar 15;180(6):4058-66 [PMID: 18322215]
  18. Bull World Health Organ. 1978;56(2):271-93 [PMID: 307456]
  19. PLoS Pathog. 2008 Nov;4(11):e1000212 [PMID: 19023410]
  20. J Infect Dis. 1999 Feb;179 Suppl 1:S1-7 [PMID: 9988155]
  21. J Infect Dis. 1999 Feb;179 Suppl 1:S65-75 [PMID: 9988167]
  22. J Exp Med. 2004 Jul 19;200(2):169-79 [PMID: 15249592]
  23. Trop Med Int Health. 2002 Dec;7(12):1068-75 [PMID: 12460399]
  24. J Immunol. 2008 Dec 1;181(11):8018-26 [PMID: 19017994]
  25. J Virol. 2005 May;79(9):5241-8 [PMID: 15827138]
  26. Cell Host Microbe. 2009 Aug 20;6(2):162-73 [PMID: 19683682]
  27. J Interferon Cytokine Res. 2004 Aug;24(8):439-54 [PMID: 15320958]
  28. Clin Exp Immunol. 2001 Jun;124(3):453-60 [PMID: 11472407]
  29. Virology. 2001 May 25;284(1):20-5 [PMID: 11352664]
  30. J Virol. 2010 Jan;84(2):1169-75 [PMID: 19889762]
  31. Cell. 2005 Sep 9;122(5):669-82 [PMID: 16125763]
  32. Int Immunol. 1999 Aug;11(8):1357-62 [PMID: 10421793]
  33. Nature. 2005 Dec 1;438(7068):575-6 [PMID: 16319873]
  34. J Leukoc Biol. 2003 Dec;74(6):1125-38 [PMID: 12960254]
  35. Nat Med. 2004 Dec;10(12 Suppl):S110-21 [PMID: 15577929]
  36. J Infect Dis. 1980 Sep;142(3):372-6 [PMID: 7441008]
  37. J Infect Dis. 1999 Feb;179 Suppl 1:S188-91 [PMID: 9988183]
  38. PLoS Pathog. 2007 Jan;3(1):e9 [PMID: 17238286]
  39. Lancet. 1995 May 20;345(8960):1271-4 [PMID: 7746057]
  40. J Exp Med. 2003 Oct 6;198(7):1043-55 [PMID: 14517278]
  41. Clin Exp Immunol. 2002 Apr;128(1):163-8 [PMID: 11982604]
  42. J Infect Dis. 1999 Feb;179 Suppl 1:S224-34 [PMID: 9988188]
  43. J Virol. 2006 Jul;80(13):6430-40 [PMID: 16775331]
  44. Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):411-6 [PMID: 19122151]
  45. Biochim Biophys Acta. 2001;1471(2):M57-62 [PMID: 11342184]
  46. J Virol. 2010 Jan;84(1):27-33 [PMID: 19846529]
  47. J Immunol. 2005 Sep 1;175(5):2851-8 [PMID: 16116171]
  48. Nature. 2001 Oct 18;413(6857):732-8 [PMID: 11607032]
  49. J Virol. 2003 Jul;77(14):7945-56 [PMID: 12829834]
  50. J Virol. 2009 Apr;83(7):3069-77 [PMID: 19153231]
  51. Science. 2001 Mar 9;291(5510):1965-9 [PMID: 11239157]
  52. Am J Trop Med Hyg. 1992 Jun;46(6):664-71 [PMID: 1621890]
  53. J Exp Med. 2004 Jun 21;199(12):1651-8 [PMID: 15210743]
  54. J Virol. 2006 Jul;80(13):6497-516 [PMID: 16775337]
  55. Int J Biochem Cell Biol. 2005 Aug;37(8):1560-6 [PMID: 15896665]
  56. Virology. 2004 Oct 25;328(2):177-84 [PMID: 15464838]
  57. Science. 2009 Jul 10;325(5937):204-6 [PMID: 19590002]
  58. Curr Opin Immunol. 2002 Aug;14(4):432-6 [PMID: 12088676]
  59. Nat Med. 1999 Apr;5(4):423-6 [PMID: 10202932]
  60. PLoS Med. 2006 Jun;3(6):e177 [PMID: 16683867]
  61. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):233-8 [PMID: 14679297]
  62. Virology. 1998 Dec 5;252(1):179-88 [PMID: 9875327]
  63. Bull World Health Organ. 1983;61(6):997-1003 [PMID: 6370486]
  64. J Infect Dis. 1999 Feb;179 Suppl 1:S108-14 [PMID: 9988173]
  65. PLoS Pathog. 2009 Jul;5(7):e1000536 [PMID: 19649327]
  66. Lancet. 2003 Dec 13;362(9400):1953-8 [PMID: 14683653]
  67. N Engl J Med. 2006 Aug 31;355(9):909-19 [PMID: 16943403]
  68. J Virol. 2006 Jun;80(11):5156-67 [PMID: 16698996]
  69. Bull World Health Organ. 1978;56(2):247-70 [PMID: 307455]
  70. J Interferon Cytokine Res. 2002 Jan;22(1):59-71 [PMID: 11846976]
  71. J Infect Dis. 1999 Feb;179 Suppl 1:S76-86 [PMID: 9988168]
  72. Nat Immunol. 2003 Nov;4(11):1144-50 [PMID: 14556004]
  73. Wkly Epidemiol Rec. 2003 Aug 15;78(33):285-9 [PMID: 14509121]
  74. J Gen Virol. 2000 Sep;81(Pt 9):2155-2159 [PMID: 10950971]
  75. Trends Immunol. 2003 Jun;24(6):286-90 [PMID: 12810098]
  76. Lancet. 2000 Jun 24;355(9222):2210-5 [PMID: 10881895]
  77. J Virol. 2006 Mar;80(6):3009-20 [PMID: 16501110]
  78. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11657-61 [PMID: 8524823]
  79. Nat Immunol. 2005 Oct;6(10):981-8 [PMID: 16127453]
  80. J Interferon Cytokine Res. 2002 Jan;22(1):87-93 [PMID: 11846979]
  81. Science. 2003 May 16;300(5622):1148-51 [PMID: 12702806]
  82. Nat Rev Immunol. 2007 Jul;7(7):556-67 [PMID: 17589545]
  83. Nat Immunol. 2004 Jul;5(7):730-7 [PMID: 15208624]
  84. J Virol. 2002 Jun;76(12):6408-12 [PMID: 12021376]
  85. Lancet. 1991 Feb 16;337(8738):425-6 [PMID: 1671441]
  86. Nature. 2003 Aug 14;424(6950):743-8 [PMID: 12872135]
  87. Science. 1968 May 24;160(3830):888-90 [PMID: 4296724]
  88. J Infect Dis. 2007 Nov 15;196 Suppl 2:S400-3 [PMID: 17940976]
  89. J Infect Dis. 1999 Feb;179 Suppl 1:S18-23 [PMID: 9988160]
  90. Ann N Y Acad Sci. 2003 Dec;1010:237-48 [PMID: 15033728]
  91. J Gen Virol. 2010 Feb;91(Pt 2):352-61 [PMID: 19828757]
  92. Immunity. 2002 Sep;17(3):251-63 [PMID: 12354379]
  93. Nat Rev Immunol. 2004 Jul;4(7):499-511 [PMID: 15229469]
  94. Lancet Infect Dis. 2004 Aug;4(8):487-98 [PMID: 15288821]
  95. Virology. 2007 Aug 1;364(2):342-54 [PMID: 17434557]
  96. Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12289-94 [PMID: 11027311]
  97. J Virol. 2007 Jan;81(1):182-92 [PMID: 17065211]
  98. Am J Pathol. 2003 Dec;163(6):2347-70 [PMID: 14633608]
  99. Lancet. 1990 Mar 3;335(8688):502-5 [PMID: 1968529]
  100. J Infect Dis. 1999 Feb;179 Suppl 1:S139-47 [PMID: 9988177]
  101. PLoS Pathog. 2007 Jun;3(6):e86 [PMID: 17590081]
  102. Br Med J. 1977 Aug 27;2(6086):541-4 [PMID: 890413]
  103. Wkly Epidemiol Rec. 1992 May 8;67(19):142-3 [PMID: 1581179]
  104. Mol Cell Biol. 1998 May;18(5):2986-96 [PMID: 9566918]
  105. Science. 1998 Dec 11;282(5396):2085-8 [PMID: 9851930]
  106. Virus Res. 2002 Aug;87(2):155-63 [PMID: 12191779]
  107. J Infect Dis. 1999 Feb;179 Suppl 1:S48-53 [PMID: 9988164]
  108. J Infect Dis. 2003 Dec 1;188(11):1618-29 [PMID: 14639531]
  109. Can Commun Dis Rep. 2003 Aug 1;29(15):129-33 [PMID: 12916393]
  110. Emerg Infect Dis. 1996 Oct-Dec;2(4):321-5 [PMID: 8969248]
  111. J Exp Med. 2004 Jun 21;199(12):1641-50 [PMID: 15210742]
  112. Nat Med. 2000 Aug;6(8):886-9 [PMID: 10932225]
  113. Nature. 2005 Oct 20;437(7062):1167-72 [PMID: 16177806]
  114. Nat Immunol. 2003 May;4(5):491-6 [PMID: 12692549]
  115. PLoS Pathog. 2009 Jun;5(6):e1000493 [PMID: 19557165]
  116. Curr Top Microbiol Immunol. 2007;316:315-34 [PMID: 17969454]
  117. Nat Med. 2005 Jul;11(7):786-90 [PMID: 15937495]
  118. Br Med J. 1975 Nov 29;4(5995):489-93 [PMID: 811315]

Grants

  1. U54 AI057158/NIAID NIH HHS

Word Cloud

Created with Highcharts 10.0.0virusimmuneresponsefilovirusviralMARVinfectionhostinnateIFNantiviralVP35filoviruseshumanEbolaEBOVkeycellsresponsesmajorprogressvaccineinfectionsimportantmolecularmechanismsproteinIFN-α/βactionVP24proteinsmembersrecognizedlethalvirusesaffectingnon-humanprimatestwogeneraFiloviridaefamilyMarburgcomprisemainetiologicagentsseverehemorrhagicfeveroutbreakscentralAfricacasefatalityratesranging2590%FataloutcomesassociatedlatedysregulatedlikelyduetargetingmacrophagesdendriticDCsnecessarymediateeffectiveadaptiveDespitedevelopmentcandidateslicensedtherapyusestillavailablelasttenyearsmadeunderstandingpathogenesisSeverallinesevidenceimplicateimpairmentinterferondeterminantvirulencevitrovivoexperimentalrecombinantZaireZEBOVbestcharacterizeddemonstratedplaysroleinhibitingproductionsynergizedinhibitioncellularminormatrixdualmaycontributeefficientinitialreplicationdisseminationNoticeablyanalogousfunctionreportedcomponentchapterreviewsrecentfindingsIFN-mediatedevasionEvasioninterferon-mediated

Similar Articles

Cited By